Radioligand Therapy Market Report 2025

The radioligand therapy market size has grown rapidly in recent years. It will grow from $6.01 billion in 2024 to $6.64 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to the increasing use of liquid biopsies, the emergence of tumor-agnostic therapies, the integration of artificial intelligence in oncology, the expanding pipeline of bispecific antibodies, and the rise in government funding for cancer research.

The radioligand therapy market size is expected to see rapid growth in the next few years. It will grow to $9.77 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to increasing investments by major pharmaceutical companies in oncology startups, greater utilization of real-world evidence, expansion of research in radiopharmaceuticals and theranostics, strengthened collaborations between academia and industry, and the rising prevalence of rare and orphan cancers. Key trends expected during this period include AI-driven design of radiopharmaceuticals, theranostics with combined imaging and therapy platforms, microfluidics-based radiotracer synthesis, development of next-generation alpha-emitting isotopes, and 3D-printed personalized dosimetry devices.

The rising incidence of cancer is expected to drive growth in the radioligand therapy market in the coming years. Cancer is characterized by the uncontrolled growth of abnormal cells that can invade surrounding tissues and spread throughout the body. The increase in cancer cases is linked to long-term exposure to environmental pollutants that damage DNA, disrupt cellular function, and promote abnormal cell proliferation. Radioligand therapy addresses cancer by delivering targeted radiation to tumor cells via ligands that bind to specific receptors, minimizing damage to healthy tissues while destroying cancer cells internally. For example, in January 2022, the American Cancer Society, a U.S.-based non-profit organization, reported that approximately 1.9 million new cancer cases and 609,360 cancer-related deaths were expected in the U.S., translating to roughly 1,670 deaths per day. Therefore, the growing prevalence of cancer is supporting the expansion of the radioligand therapy market.

Companies in the radioligand therapy market are increasingly focusing on the development of advanced facilities to improve production efficiency while ensuring consistent quality and safety standards in the manufacturing and distribution of targeted cancer treatments. Radioligand therapy facilities are specialized centers equipped to handle and deliver radioactive drugs for targeted cancer therapy, employing advanced imaging systems and radiation shielding, along with trained personnel and strict safety protocols. For instance, in January 2024, Novartis AG, a Switzerland-based pharmaceutical company, announced the automation of its new large-scale radioligand therapy (RLT) production plant in Indiana, which received Food and Drug Administration (FDA) approval for commercial manufacturing. This 70,000-square-foot facility is the largest and most advanced Novartis site dedicated to RLT, featuring fully automated production lines designed for efficient, time-sensitive manufacturing to meet rising patient demand in the U.S. and Canada.

In December 2023, Eli Lilly and Company, a U.S.-based pharmaceutical firm, acquired POINT Biopharma Global Inc. for \$1.4 billion. This acquisition strengthens Eli Lilly’s oncology portfolio by integrating advanced radioligand therapy capabilities to enhance precision cancer treatment options. POINT Biopharma Global Inc., also based in the U.S., specializes in the development of radioligand therapies for cancer.

Major players in the radioligand therapy market are Bayer AG, Novartis AG, Eli Lilly and Company, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Molecular Partners AG, Telix Pharmaceuticals, Nanobiotix S.A., Mariana Oncology Inc., Artios Pharma Limited, AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc., OncoSil Medical Ltd.

North America was the largest region in the radioligand therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in radioligand therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the radioligand therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Radioligand therapy (RLT) is an advanced targeted cancer treatment that attaches a radioactive isotope to a ligand specifically designed to bind to cancer cell receptors. Once administered, it targets tumor cells and delivers precise radiation directly to them, minimizing damage to healthy tissues. This targeted mechanism helps reduce side effects and enhances treatment outcomes, particularly in cases resistant to conventional therapies.

The primary types of radioligands used in RLT include alpha emitters, beta emitters, Auger emitters, and combined emission radioligands. Alpha emitters release high-energy alpha particles over very short distances, typically a few cell layers, making them highly effective for precise cell destruction. These radioligands are engineered to bind to specific molecular targets, such as hormone receptors, growth factor receptors, tumor antigen markers, and others. They can be administered via multiple routes, including intravenous (IV), intramuscular (IM), subcutaneous, and oral. Radioligand therapy is applied in treating a variety of conditions, including oncological and cardiovascular disorders, neurological diseases, and infectious diseases, and is utilized across hospitals, diagnostic laboratories, research institutions, and home care settings.

The radioligand therapy market research report is one of a series of new reports that provides radioligand therapy market statistics, including the radioligand therapy industry global market size, regional shares, competitors with the radioligand therapy market share, detailed radioligand therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the Radioligand therapy industry. This radioligand therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The radioligand therapy market consists of revenues earned by entities by providing services such as targeted treatment services, diagnostic imaging, and clinical and infrastructure services. The market value includes the value of related goods sold by the service provider or included within the service offering. The radioligand therapy market also includes sales of somatostatin receptor ligands, radiolabeled bombesin analogs, radiolabeled monoclonal antibodies, and prostate-specific membrane antigen (PSMA)-targeted ligands. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.